Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.

ABSTRACT:

Purpose

Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging. Mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in most LGGs (> 70%). Ivosidenib is an inhibitor of mutant IDH1 (mIDH1) under evaluation in patients with solid tumors.

Methods

We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with mIDH1 solid tumors. Ivosidenib was administered orally daily in 28-day cycles.

Results

In 66 patients with advanced gliomas, ivosidenib was well tolerated, with no dose-limiting toxicities reported. The max

SUBMITTER: Mellinghoff IK 

PROVIDER: S-EPMC7527160 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature